PURPOSE: While anal cancer is a very rare oncological diagnosis representing less than 2% of lower gastrointestinal tract cancers, the incidence has doubled in the past 20 years. Radical radiochemotherapy with sequential or simultaneous boost is now the standard treatment modality. Interstitial HDR brachytherapy is one of the boost application options. Implementation of new radiotherapy techniques has resulted in improved therapeutic outcomes; however, it is still associated with acute and especially late toxicity. Gastrointestinal disorders and sexual dysfunction are the most frequent factors affecting the long-term quality of cured patients' lives. METHODS: A total of 96 patients consecutively treated between 2000 and 2022 with external beam radio-/chemotherapy and an interstitial brachytherapy boost for histologically verified nonmetastatic anal squamous cell carcinoma were evaluated. The median follow-up time was 15.4 years (range 13.4-17.3 years). The primary objective of the study was to assess local control (LC) and quality of life (QoL). The Czech versions of internationally validated EORTC questionnaires were used to evaluate life quality-the basic EORTC QOL-C30 v.3 and the specific QOL-ANL 27 questionnaire. RESULTS: Local control was 85.5% at 5 years, 83.4% at 10 years, 83.4% at 15 years, and 83.4% at 20 years, and there was no dependence on clinical stage. The most common forms of acute toxicity were cutaneous and hematological but were gastrointestinal for late toxicities. In the evaluation of quality of life, 80.5% of patients alive at the time participated. In the EORTC quality of life questionnaire C30 v.3, patients rated the functional scale score as 86.2 points (standard deviation [SD] = 12.6) and the symptom score as 15.5 points (SD = 12.5). The global health score achieved 68.4 points (SD = 23.6). The most common symptoms were fatigue with 25.6 points (SD = 20.2) and diarrhea with 19.0 points (SD = 27.8). In the QOL-ANL 27 questionnaire, symptom scales assessing bowel symptoms were scored 27.5 points (SD = 19) in non-stoma patients and 11.9 points (SD = 17.2) in stoma patients. In the single-item symptom scales, the highest scores were rated for frequency of urination with 26.4 points (SD = 30.8), need to be close to a toilet with 22.4 points (SD = 27.3), and self-cleaning more often with 25.3 points (SD = 31.8). In the functional scales assessing sex life and interest, men and women reported scores of 45.2 (SD = 23) and 45.5 points (SD = 19), respectively. CONCLUSION: Boost with interstitial HDR brachytherapy is an established safe method of anal cancer treatment, with excellent results and limited late toxicity. Functioning scales were rated relatively highly in QoL questionnaires, and the overall global health score was comparable to published data. Gastrointestinal difficulties, fatigue, and sexual dysfunction dominated the symptom scales in our cohort.

2nd Faculty of Medicine Charles University Prague 5 Úvalu 84 150 06 Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer University Hospital Prague Vídeňská 800 140 59 Prague Czech Republic

Department of Oncology 2nd Faculty of Medicine Charles University and Motol University Hospital 5 Úvalu 84 150 06 Prague Czech Republic

Zobrazit více v PubMed

National Cancer Institute Surveillance, epidemiology, and end results program. Cancer stat facts: anal cancer. https://seer.cancer.gov/statfacts/html/anus.html

Kang Y‑J, Smith M, Canfell K (2018) Anal cancer in high-income countries: increasing burden of disease. PLoS ONE 13(10):e205105. 10.1371/journal.pone.0205105 PubMed PMC

Deshmukh AA, Suk R, Shiels MS, Sonawane K, Nyitray AG, Liu Y, Gaisa MM, Palefsky JM, Sigel K (2020) Recent trends in squamous cell carcinoma of the anus incidence and mortality in the United States, 2001–2015. J Natl Cancer Inst 112(8):829–838. 10.1093/jnci/djz219 PubMed PMC

Islami F, Ferlay J, Lortet-Tieulent J, Bray F, Ahmedin J (2017) International trends in anal cancer incidence rates. Int J Epidemiol 46(3):924–938. 10.1093/ije/dyw276 PubMed

Lin C, Franceschi S, Clifford GM (2018) Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis 18(2):198–206. 10.1016/S1473-3099(17)30653-9 PubMed PMC

Kelly H, Chikandiwa A, Alemany Vilches L, Palefsky JM, de Sanjose S, Mayaud P (2020) Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. Lancet HIV 7(4):e262–e278. 10.1016/S2352-3018(19)30434-5 PubMed

Hoff PM, Coudry R, Moniz CM (2017) Pathology of anal cancer. Surg Oncol Clin N Am 26(1):57–71. 10.1016/j.soc.2016.07.013 PubMed

Urbute A, Rasmussen CL, Belmonte F, Obermueller T, Prigge ES, Arbyn M, Verdoodt F, Kjaer SK (2020) Prognostic significance of HPV DNA and p16 PubMed

Obermueller T, Hautekiet J, Busto MP, Reynders D, Belgioia L, Cats A, Gilbert DC, Koerber SA, Mai S, Meulendijks D, Rödel F, Yhim HY, Hetjens S, Weiß C, Rasmussen CL, Urbute A, Verdoodt F, Kjaer SK, Reuschenbach M, Goetghebeur E, von Knebel Doeberitz M, Arbyn M, Prigge ES (2021) Prognostic value of high-risk human papillomavirus DNA and p16 PubMed

Mahmud A, Poon R, Jonker D (2017) PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol 90(1080):20170370. 10.1259/bjr.20170370 PubMed PMC

Lohynska R, Mazana E, Novakova-Jiresova A, Jirkovska M, Nydlova A, Veselsky T, Malinova B, Buchler T, Stankusova H (2020) Improved survival in patients with FDG-PET/CT-based radiotherapy treatment planning for squamous cell anal cancer. Neoplasma 67(5):1157–1163. 10.4149/neo_2020_191229N1350 PubMed

Secerov Ermenc A, Segedin B (2023) The role of MRI and PET/CT in radiotherapy target volume determination in gastrointestinal cancers-review of the literature. Cancers 15(11):2967. 10.3390/cancers15112967 PubMed PMC

Boman BM, Moertel CG, O’Connell MJ, Scott M, Weiland LH, Beart RW, Gunderson LL, Spencer RJ (1984) Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 54(1):114–125. 10.1002/1097-0142(19840701)54:1 PubMed

Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG (1989) Radiotherapy for anal cancer: experience from 1979–1987. Int J Radiat Oncol Biol Phys 17(6):1153–1160. 10.1016/0360-3016(89)90520-8 PubMed

Nigro ND, Vaitkevicius VK, Considine B Jr. (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17(3):354–356. 10.1007/BF02586980 PubMed

Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15(5):2040–2049. 10.1200/JCO.1997.15.5.2040 PubMed

Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14(9):2527–2539. 10.1200/JCO.1996.14.9.2527 PubMed

Gunderson LL, Moughan J, Ajani JA, Pedersen JE, Winter KA, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett CG (2013) Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98–11 phase 3 trial. Int J Radiat Oncol Biol Phys 87(4):638–645. 10.1016/j.ijrobp.2013.07.035 PubMed PMC

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D (2013) Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomized, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol 14(6):516–524. 10.1016/S1470-2045(13)70086-X PubMed

UKCCCR Anal Cancer Trial Working Party, UK Co-ordinating Committee on Cancer Research (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5‑fluorouracil, and mitomycin. Lancet 348(9034):1049–1054 PubMed

Ajani JA, Winter KA, Gunderson LL et al (2008) Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299(16):1914–1921. 10.1001/jama.299.16.1914 PubMed

Werner RN, Gaskins M, Avila VG, Budach V, Koswig S, Mosthaf FA, Raab HR, Rödel C, Nast A, Siegel R, Aigner F (2021) State of the art treatment for stage I to III anal squamous cell carcinoma: a systematic review and meta-analysis. Radiother Oncol. 10.1016/j.radonc.2021.01.031 PubMed

Gouriou C, Lemanski C, Pommier P, Le Malicot K, Saint A, Rivin Del Campo E, Evin C, Quero L, Regnault P, Baba-Hamed N, Ronchin P, Crehange G, Tougeron D, Menager-Tabourel E, Diaz O, Hummelsberger M, de la Rocherfordiere A, Drouet F, Vendrely V, Lièvre A (2024) Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE. Br J Cancer 130(5):769–776. 10.1038/s41416-023-02564-9 PubMed PMC

Vendrely V, Lemanski C, Pommier P, Malicot LEK, Saint A, Rivin Del Campo E, Regnault P, Baba-Hamed N, Ronchin P, Crehange G, Tougeron D, Menager-Tabourel E, Diaz O, Hummelsberger M, Minsat M, Drouet F, Larrouy A, Peiffert D, Lievre A, Zasadny X, Hautefeuille V, Mornex F, Lepage C, Quero L (2023) Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-ANABASE. Radiother Oncol 183:109542. 10.1016/j.radonc.2023.109542 PubMed

Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, Augspurger ME, Schefter TE, Katz AW, Fisher BJ, Henke LE, Narayan S, Crane CH (2022) Long-term outcomes of NRG oncology/RTOG 0529: a phase 2 evaluation of dose-paired intensity modulated radiation therapy in combination with 5‑Fluorouracil and mitomycin‑C for the reduction of acute morbidity in anal canal cancer. Int J Radiat Oncol Biol Phys 112(1):146–157. 10.1016/j.ijrobp.2021.08.008 PubMed PMC

Rao S, Guren MG, Khan K, Brown G, Renehan AG, Steigen SE, Deutsch E, Martinelli E, Arnold D, ESMO Guidelines Committee (2021) Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(9):1087–1100. 10.1016/j.annonc.2021.06.015 PubMed

Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D, European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO), European Society of Radiotherapy and Oncology (ESTRO) (2014) Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol 40(10):1165–1176. 10.1016/j.ejso.2014.07.030 PubMed

Petric P, Al-Hammadi N, Spindler KG, Lindegaard JC (2022) Anal cancer brachytherapy: From radon seeds to interstitial papillon technique in a century. What does the future hold? Radiother Oncol. 10.1016/j.radonc.2022.02.006 PubMed

Ali ZS, Solomon E, Mann P, Wong S, Chan KKW, Taggar AS (2022) High dose rate brachytherapy in the management of anal cancer: a review. Radiother Oncol 171:43–52. 10.1016/j.radonc.2022.03.019 PubMed

Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M, Cvitkovic F, Mirabel X, Bouché O, Luporsi E, Conroy T, Montoto-Grillot C, Mornex F, Lusinchi A, Hannoun-Lévi JM, Seitz JF, Adenis A, Hennequin C, Denis B, Ducreux M (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30(16):1941–1948. 10.1200/JCO.2011.35.4837 (Erratum in: J Clin Oncol. 2012. 30(31):3903) PubMed

Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, McDonald AC, Myint S, Samuel L, Sebag-Montefiore D, National Cancer Research Institute Anal Sub Group, Colorectal Clinical Oncology Group (2008) EXTRA—a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 72(1):119–126. 10.1016/j.ijrobp.2007.12.012 PubMed

Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A (2014) Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 111(9):1726–1733. 10.1038/bjc.2014.467 PubMed PMC

Oliveira SC, Moniz CM, Riechelmann R, Alex AK, Braghirolli MI, Bariani G, Nahas C, Hoff PM (2016) Phase II study of capecitabine in substitution of 5‑FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer 47(1):75–81. 10.1007/s12029-015-9790-4 PubMed

Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF (1997) Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 39(3):651–657. 10.1016/s0360-3016(97)00329-5 PubMed

Muirhead R, Partridge M, Hawkins MA (2015) A tumor control probability model for anal squamous cell carcinoma. Radiother Oncol 116(2):192–196. 10.1016/j.radonc.2015.07.014 PubMed

Sebag-Montefiore D, Adams R, Bell S, Berkman L, Gilbert D, Glynne-Joones R, Goh V, Gregory W, Harrison M, Kachnic L et al (2017) EP-1277: Optimising RT dose for anal cancer—the development of three clinical trials in one platform. Radiother Oncol 123:685–S686

Frakulli R, Buwenge M, Cammelli S, Macchia G, Farina E, Arcelli A, Ferioli M, Fuccio L, Tagliaferri L, Galuppi A, Frezza GP, Morganti AG (2018) Brachytherapy boost after chemoradiation in anal cancer: a systematic review. J Contemp Brachytherapy 10(3):246–253. 10.5114/jcb.2018.76884 PubMed PMC

Gryc T, Ott O, Putz F, Knippen S, Raptis D, Fietkau R, Strnad V (2016) Interstitial brachytherapy as a boost to patients with anal carcinoma and poor response to chemoradiation: single-institution long-term results. Brachytherapy 15(6):865–872. 10.1016/j.brachy.2016.08.003 PubMed

Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF (2007) Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy 6(3):218–226. 10.1016/j.brachy.2007.02.152 PubMed

Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M (2008) The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 87(3):383–390. 10.1016/j.radonc.2008.04.011 PubMed

Bentzen AG, Guren MG, Vonen B, Wanderås EH, Frykholm G, Wilsgaard T, Dahl O, Balteskard L (2013) Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiother Oncol 108(1):55–60. 10.1016/j.radonc.2013.05.037 PubMed

Kronborg CJS, Christensen P, Pedersen BG, Spindler KG (2021) Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer. Radiother Oncol 157:141–146. 10.1016/j.radonc.2021.01.027 PubMed

Varela Cagetti L, Moureau-Zabotto L, Zemmour C, Ferré M, Giovaninni M, Poizat F, Lelong B, De Chaisemartin C, Mitry E, Tyran M, Zioueche-Mottet A, Salem N, Tallet A (2023) The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments. Brachytherapy 22(4):531–541. 10.1016/j.brachy.2023.03.004 PubMed

Joseph K, Balushi MA, Ghosh S, Stenson T, Abraham A, Elangovan A, Warkentin H, Paulson K, Tankel K, Usmani N, Severin D, Schiller D, Wong C, Mulder K, Doll C, King K, Nijjar T (2023) Long-term patient-reported quality of life of anal cancer survivors treated with intensity modulated radiation therapy and concurrent chemotherapy: results from a prospective phase II trial. Int J Radiat Oncol Biol Phys 117(2):434–445. 10.1016/j.ijrobp.2023.04.023 PubMed

Sterner A, Derwinger K, Staff C, Nilsson H, Angenete E (2019) Quality of life in patients treated for anal carcinoma—a systematic literature review. Int J Colorectal Dis 34(9):1517–1528. 10.1007/s00384-019-03342-x PubMed

Rooney MK, Niedzielski JS, Salazar RM, Arzola A, Das P, Koay EJ, Koong A, Ludmir EB, Minsky BD, Noticewala S, Smith GL, Taniguchi C, Holliday EB (2024) Long-term patient-reported dyspareunia after definitive chemoradiation for anal cancer: using the anterior vaginal wall as an organ-at-risk to define an actionable dosimetric goal. Radiat Oncol 9(5):101449. 10.1016/j.adro.2024.101449 PubMed PMC

Tom A, Bennett AV, Rothenstein D, Law E, Goodman KA (2018) Prevalence of patient-reported gastrointestinal symptoms and agreement with clinician toxicity assessments in radiation therapy for anal cancer. Qual Life Res 27(1):97–103. 10.1007/s11136-017-1700-8 PubMed

Aaronson NK et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376 PubMed

Sodergren SC, Johnson CD, Gilbert A, Darlington AS, Cocks K, Guren MG, Rivin Del Campo E, Brannan C, Christensen P, Chu W, Chung H, Dennis K, Desideri I, Gilbert DC, Glynne-Jones R, Jefford M, Johansson A, Juul T, Kardamakis D, Lai-Kwon J, McFarlane V, Miguel IMC, Nugent K, Peters F, Riechelmann RP, Turhal NS, Wong S, Vassiliou V, European Organisation for Research and Treatment of Cancer Quality of Life Group (2022) International validation of the EORTC QLQ-ANL27, a field study to test the anal cancer-specific health-related quality of life questionnaire. Int J Radiat Oncol Biol Phys. 10.1016/j.ijrobp.2022.11.002 PubMed

Sauter C, Peeken JC, Borm K, Diehl C, Münch S, Combs SE, Dapper H (2022) Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer. Sci Rep 12(1):4416. 10.1038/s41598-022-08525-1 PubMed PMC